Positive Long-Term VenoValve(R) First-in-Human Data Presented at 34th Annual Meeting of the American Venous Forum

Author's Avatar
Feb 25, 2022

- First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 30 months post-surgery
- No venous ulcer recurrences, relapses of CVI, or safety issues
- Improvements in average Reflux, disease manifestations (VCSS), and pain (VAS) endpoints continue to be encouraging